Wall Street brokerages predict that ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) will post earnings per share (EPS) of ($0.44) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for ESSA Pharma’s earnings. ESSA Pharma reported earnings per share of ($0.83) in the same quarter last year, which suggests a positive year over year growth rate of 47%. The company is expected to issue its next quarterly earnings results on Monday, May 13th.
On average, analysts expect that ESSA Pharma will report full year earnings of ($1.48) per share for the current year, with EPS estimates ranging from ($1.84) to ($1.11). For the next financial year, analysts anticipate that the firm will post earnings of ($1.30) per share, with EPS estimates ranging from ($1.49) to ($1.11). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for ESSA Pharma.
ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last announced its quarterly earnings results on Thursday, February 7th. The company reported ($0.42) earnings per share for the quarter.
Separately, HC Wainwright reiterated a “buy” rating on shares of ESSA Pharma in a research report on Friday, February 15th.
Shares of EPIX stock opened at $2.38 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.54 and a quick ratio of 3.54. The company has a market cap of $15.02 million, a P/E ratio of -0.93 and a beta of 2.55. ESSA Pharma has a twelve month low of $1.87 and a twelve month high of $5.83.
ESSA Pharma Company Profile
ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.